Pink SheetMerck ’s blockbuster cancer drug Keytruda received a one-year reprieve from selection for the Medicare price negotiation program with the enactment of Republicans’ budget reconciliation bill. The legi
Pink SheetThe US Food and Drug Administration’s complete response letter for Replimune ’s RP1 appears to point the company in a different direction than its previous interactions with the agency, providing fur
ScripThe US Food and Drug Administration’s complete response letter for Replimune’s biologics license application for RP1 (vusolimogene oderparepvec), a novel oncolytic immunotherapeutic for the treatment
ScripChinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat